JPMorgan analyst Robbie Marcus downgraded Inspire Medical (INSP) to Neutral from Overweight with a price target of $110, down from $195. The company’s Q2 update was “disappointing” with a significant cut to 2025 guidance, the analyst tells investors in a research note. The firm believes investors will struggle to separate Inspire’s logistics and execution issues from underlying demand issues. It cites uncertain demand trends for the Inspire V launch and execution issues for the downgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical downgraded to Sector Weight from Overweight at KeyBanc
- Inspire Medical Systems Reports Q2 2025 Financials
- Closing Bell Movers: Palantir hits record highs on beat and raise
- Inspire Medical Systems Reports Q2 2025 Financial Results
- Inspire Medical down 22% after reporting Q2 earnings, lowering FY25 guidance